Takeda Pharmaceutical Current Deferred Revenue Over Time
| TAK Stock | USD 13.38 0.05 0.38% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Takeda Pharmaceutical Performance and Takeda Pharmaceutical Correlation. Takeda |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.049 | Dividend Share 192 | Earnings Share 0.59 | Revenue Per Share 1.4 K | Quarterly Revenue Growth 0.127 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare Takeda Pharmaceutical and related stocks such as Viatris, Elanco Animal Health, and Zoetis Inc Current Deferred Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VTRS | 73 M | 44.1 M | (1.2 B) | 835.1 M | 1.2 B | 1.3 B | (939.5 M) | (976 M) | (1.1 B) | (1.1 B) | 3.6 B | 4.1 B | 3.1 B | 3.1 B | 3.2 B |
| ELAN | 367.6 M | 367.6 M | 367.6 M | 367.6 M | 367.6 M | 367.6 M | 367.6 M | 367.6 M | 367.6 M | 116 M | 148.6 M | 185 M | 524 M | 602.6 M | 632.7 M |
| ZTS | 168 M | 224 M | 224 M | 305 M | 781 M | 1 B | 35 M | 35 M | 35 M | 950 M | 1 B | 6 M | 5 M | 4.5 M | 4.3 M |
| EBS | 18.3 M | 1.4 M | 1.8 M | 1.8 M | 5.3 M | 7.9 M | 7 M | 13.2 M | 10.6 M | 101.9 M | 131.5 M | 140.4 M | 26.4 M | 30.4 M | 28.1 M |
| PBH | (2 M) | 836 K | 836 K | 836 K | 836 K | 836 K | 492 K | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 3 M | 1.9 M |
| AMPH | 642 K | 642 K | 642 K | 643 K | 14 M | 643 K | 97 K | (56.1 M) | (56.1 M) | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.4 M | 1.5 M |
| PCRX | 2 M | 13.1 M | 972 K | 1 M | 1.4 M | 1.4 M | 595 K | 102 K | 71.8 M | 71.8 M | 71.1 M | 10.1 M | 34 M | 39.1 M | 41.1 M |
| COLL | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | 4.9 M | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (14.4 M) | (13.7 M) |
| SIGA | 347.3 K | 41 B | 57.1 B | 162.2 B | 81.8 M | 255.3 B | 367.5 B | 1.3 M | 4.2 M | 2.3 M | 3.3 M | 3.8 M | 10.6 M | 20.8 M | 19.7 M |
| ESPR | 1.2 M | 1.2 M | 1.2 M | 107 K | 107 K | 37 K | 40 K | 38 K | 2.2 M | 2.2 M | 1.7 M | 5.7 M | 3.5 M | 25.4 M | 26.7 M |
| CTLT | 25.4 M | 25.4 M | 36.3 M | 47.1 M | 39 M | 46.2 M | 84.9 M | 100.9 M | 155.2 M | 191 M | 305 M | 185 M | 167 M | 250 M | 138.2 M |
| EVO | 3.4 M | 18.2 M | 5.8 M | 6.3 M | 3.3 M | 8.9 M | 15.9 M | 19 M | 61.2 M | 73.4 M | 70.6 M | 126.8 M | 136.7 M | 107.9 M | 113.2 M |
| NBIX | 5.4 M | 37.3 M | 2.9 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | (46.2 M) | (10.3 M) | (16.5 M) | 229.3 M | 263.7 M | 276.9 M |
| PAHC | 30.8 M | 30.8 M | 30.8 M | 30.8 M | 33.9 M | 33.9 M | 41.4 M | 3.6 M | 52.8 M | 44.8 M | 58.9 M | 822 K | 54.9 M | 10.2 M | 9.7 M |
| TEVA | 43.7 M | 2.6 B | 1.1 B | 1.1 B | 993 M | 735 M | 725 M | 11.4 B | 9.4 B | 8.7 B | 7.3 B | 7 B | 1.5 B | 4.9 B | 3.1 B |
| HLN | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 7 M | 11 M | 11 M | 23 M | 288 M | 302.4 M |
| BHC | 26.3 M | 12.8 M | 7 M | 19.5 M | 18.8 M | 16.6 M | 26 M | 2.7 B | 167 M | 2.4 B | (52 M) | (49.9 M) | 2.1 B | 2.4 B | 2.5 B |
Takeda Pharmaceutical and related stocks such as Viatris, Elanco Animal Health, and Zoetis Inc Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
| Takeda Pharmaceutical Co | TAK |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Japan |
| Exchange | New York Stock Exchange |
USD 13.38
Check out Takeda Pharmaceutical Performance and Takeda Pharmaceutical Correlation. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Takeda Pharmaceutical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.